Insmed To Present Novel Inhalation PAH Treatment at European Respiratory Society’s International Congress

Insmed To Present Novel Inhalation PAH Treatment at European Respiratory Society’s International Congress

Insmed PAH drugBiopharm company, Insmed Incorporated, has announced that they will present their novel inhalation technologies for the treatment of orphan pulmonary diseases such as pulmonary arterial hypertension at the European Respiratory Society’s (ERS) International Congress 2014. Held between September 6th and 10th at the Internationales Congress Center München, in Munich, Germany, the congress will include several clinical and scientific presentations on respiratory diseases.

The company’s presentation will focus on INS-1009 (treprostinil), a novel inhalation formulation of prostacyclin for the treatment of pulmonary arterial hypertension (PAH). “The introduction of INS-1009 is testament to our innovative research and development team and underscores our commitment to new treatments for orphan lung diseases,” said Will Lewis, the president and chief executive officer of Insmed. “We believe we can address the current limitations of inhaled prostacyclin therapies in PAH with our proven design, development and formulation expertise.”

[adrotate group=”4″]

Insmed is dedicated to improving product design, drug development, and sustained-release formulation expertise in order to advance INS-1009, as well as addressing current limitations of the available inhaled prostacyclin therapies for the treatment of PAH. INS-1009 is a once-daily inhalated therapy, designed to provide consistent, effective drug levels, and is also expected to reduce the acute systemic effects of current treatment options.

“We believe INS-1009 and its sustained-release inhaled formulation of prostacyclin may prolong duration of effect and provide greater consistency in the reduction of pulmonary arterial pressure over time. As a result, this may reduce the acute impact of drug treatment on heart rate, blood pressure and the severity and/or frequency of cough,” stated Walter Perkins, Ph.D., chief technology officer of Insmed. “Moreover, current inhaled prostacyclin therapies must be dosed four to nine times per day. Reducing dose frequency to once-daily would ease patient burden and may positively impact compliance.”

[adrotate group=”3″]

In addition, the company will present data regarding ARIKAYCE, or liposomal amikacin for inhalation delivered by an investigational eFlow Nebulizer System (PARI Pharma GmbH), for the treatment of both nontuberculous mycobacteria lung infections (NTM) and Pseudomonas aeruginosa for patients with cystic fibrosis (CF).

“We are particularly pleased to have the depth of data presented on ARIKAYCE in both NTM and Pseudomonas aeruginosa in cystic fibrosis patients as we move forward with plans to submit for licensure with the European Medicines Agency in both indications,” MR. Lewis added.

The schedule of PH-related presentations include:

Session 257: Thematic Poster Session: Pulmonary hypertension: novel targets and drugs 
Title: Incorporation into lipid nanoparticles extends the duration of activity of treprostinil in an acute hypoxia rat model of pulmonary arterial hypertension
Day/Date: Monday, September 8, 2014
Session Time: 12:50 p.m. – 2:40 p.m.
Poster Board: #P2357
Room: Hall B2-19

Session 257: Thematic Poster Session: Pulmonary hypertension: novel targets and drugs
Title: Treprostinil prodrugs for pulmonary arterial hypertension evaluated in cAMP profiling studies in live CHO-K1 cells
Day/Date: Monday, September 8, 2014
Session Time: 12:50 p.m. – 2:40 p.m.
Poster Board: #P2358
Room: Hall B2-19

Session 257: Thematic Poster Session: Pulmonary hypertension: novel targets and drugs 
Title: Prolonged activity of inhaled treprostinil prodrug-nanoparticles in a rat model of pulmonary arterial hypertension
Day/Date: Monday, September 8, 2014
Session Time: 12:50 p.m. – 2:40 p.m.
Poster Board: #P2356
Room: Hall B2-19

Session 257: Thematic Poster Session: Pulmonary hypertension: novel targets and drugs 
Title: Treprostinil pharmacokinetics in rats are extended using inhaled prodrug formulations
Day/Date: Monday, September 8, 2014
Session Time: 12:50 p.m. – 2:40 p.m.
Poster Board: #P2367
Room: Hall B2-19

Related Post

Leave a Comment

Your email address will not be published. Required fields are marked *